Literature DB >> 3927300

Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding.

R Clark, G Wong, N Arnheim, D Nitecki, F McCormick.   

Abstract

An antibody (anti-p21ser) was raised against a ras p21-related synthetic peptide and was able to recognize specifically the substitution of serine for glycine at amino acid 12 of p21. This substitution causes oncogenic activation of p21. Anti-p21ser was found to immunoprecipitate v-Ki-ras p21 and to strongly inhibit its ability to autophosphorylate and to bind GTP in an immunoabsorption assay. Furthermore, binding of the antibody to p21 was specifically inhibited by GTP or GDP, suggesting that amino acids around position 12 are part of the GTP/GDP binding site. These results, taken together with the observation that the microinjection of anti-p21ser into cells transformed by v-Ki-ras p21 causes a transient reversion of the cells to a normal phenotype [Feramisco, J. R., Clark, R., Wong, G., Arnheim, N., Milley, R. & McCormick, F. (1985) Nature (London) 314, 639-642], support the idea that interaction of p21 with guanine nucleotides is crucial to the transforming function of this protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927300      PMCID: PMC390551          DOI: 10.1073/pnas.82.16.5280

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein.

Authors:  J R Feramisco; R Clark; G Wong; N Arnheim; R Milley; F McCormick
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

Review 2.  Solid-phase peptide synthesis.

Authors:  R B Merrifield
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1969

3.  Tapping the immunological repertoire to produce antibodies of predetermined specificity.

Authors:  R A Lerner
Journal:  Nature       Date:  1982-10-14       Impact factor: 49.962

4.  Homology between human bladder carcinoma oncogene product and mitochondrial ATP-synthase.

Authors:  N J Gay; J E Walker
Journal:  Nature       Date:  1983-01-20       Impact factor: 49.962

5.  Predicted nucleotide-binding properties of p21 protein and its cancer-associated variant.

Authors:  R K Wierenga; W G Hol
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

6.  Structural features of the GDP binding site of elongation factor Tu from Escherichia coli as determined by x-ray diffraction.

Authors:  J R Rubin; K Morikawa; J Nyborg; T F la Cour; B F Clark; D L Miller
Journal:  FEBS Lett       Date:  1981-06-29       Impact factor: 4.124

7.  Antibodies specific for the carboxy- and amino-terminal regions of simian virus 40 large tumor antigen.

Authors:  G Walter; K H Scheidtmann; A Carbone; A P Laudano; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

8.  Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus.

Authors:  T Y Shih; A G Papageorge; P E Stokes; M O Weeks; E M Scolnick
Journal:  Nature       Date:  1980-10-23       Impact factor: 49.962

9.  Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses.

Authors:  T Y Shih; P E Stokes; G W Smythers; R Dhar; S Oroszlan
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

10.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

View more
  16 in total

1.  Monoclonal antibody Y13-259 recognizes an epitope of the p21 ras molecule not directly involved in the GTP-binding activity of the protein.

Authors:  J C Lacal; S A Aaronson
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

2.  ras p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function.

Authors:  J C Lacal; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 3.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

Review 4.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

5.  Mutational analysis of a ras catalytic domain.

Authors:  B M Willumsen; A G Papageorge; H F Kung; E Bekesi; T Robins; M Johnsen; W C Vass; D R Lowy
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

6.  P21 v-ras inhibits induction of c-myc and c-fos expression by platelet-derived growth factor.

Authors:  J N Zullo; D V Faller
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

7.  Heterologous expression and characterization of the human R-ras gene product.

Authors:  D G Lowe; D V Goeddel
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

8.  Expression of the Kirsten ras viral and human proteins in Escherichia coli.

Authors:  E T Nakano; M M Rao; M Perucho; M Inouye
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Mutations of the ras gene product p21 that abolish guanine nucleotide binding.

Authors:  D J Clanton; S Hattori; T Y Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.